Solriamfetol delivers measurable wakefulness gains for early‑morning shift workers with shift work disorder
Clinical trial data show solriamfetol can modestly but reliably increase wakefulness in people with shift work disorder who start work…
FLOW trial: Sulthiame produced dose-dependent 16–35% AHI reductions — a pharmacologic option for CPAP‑intolerant OSA patients
Sulthiame, an oral carbonic anhydrase inhibitor, cut apnea events in the FLOW Phase 2 trial by roughly 16–35% depending on…